Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Randomized, Double Blinded PhaseI/IIa Exploratory Study to Evaluate Reactogenicity, Safety, Immunogenicity and Dose Response of a New Hepatitis B Vaccine in Human Adult

NCT02692170 is registered in ClinicalTrials.gov with Aribio Lab Co., Ltd. as lead sponsor.

NCT NCT02692170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02692170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Randomized, Double Blinded PhaseI/IIa Exploratory Study to Evaluate Reactogenicity, Safety, Immunogenicity and Dose Response of a New Hepatitis B Vaccine in Human Adult
Lead sponsor
Aribio Lab Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
December 7, 2012
Completion date
May 28, 2015
Enrollment
75 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy